C24 dihydro Ceramide (d18:0/24:0)
(Synonyms: Cer(d18:0/24:0)) 目录号 : GC43075A sphingolipid
Cas No.:6063-36-1
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
C24 dihydro Ceramide is a sphingolipid that has been found in the stratum corneum of human skin.[1] It is found in higher concentrations in female sebum compared to male sebum.[2] C24 dihydro Ceramide levels positively correlate with cytotoxicity in CCRF-CEM, MOLT-4, COG-LL-317h, and COG-LL-332h T cell acute lymphoblastic leukemia (ALL) cell lines.[4] Levels of C24 dihydro ceramide are increased by 149.49-fold in dihydroceramide desaturase 1 (DEGS1) knockdown UM-SCC-22A human head and neck squamous carcinoma cells in vitro.[4] C24 dihydro Ceramide levels are also increased in INS-1 β-cells incubated with glucose and palmitate.[5]
Reference:
[1]. Farwanah, H., Wohlrab, J., Neubert, R.H., et al. Profiling of human stratum corneum ceramides by means of normal phase LC/APCI-MS. Anal. Bioanal. Chem. 383(4), 632-637 (2005).
[2]. Agrawal, K., Hassoun, L.A., Foolad, N., et al. Effects of atopic dermatitis and gender on sebum lipid mediator and fatty acid profiles. Prostaglandins Leukot. Essent. Fatty Acids 134, 7-16 (2018).
[3]. Holliday, M.W., Jr., Cox, S.B., Kang, M.H., et al. C22:0- and C24:0-dihydroceramides confer mixed cytotoxicity in T-cell acute lymphoblastic leukemia cell lines. PLoS One 8(9), (2013).
[4]. Breen, P., Jospeh, N., Thompson, K., et al. Dihydroceramide desaturase knockdown impacts sphingolipids and apoptosis after photodamage in human head and neck squamous carcinoma cells. Anticancer Res. 33(1), 77-84 (2013).
[5]. Véret, J., Coant, N., Berdyshev, E.V., et al. Ceramide synthase 4 and de novo production of ceramides with specific N-acyl chain lengths are involved in gluco-lipotoxicity-induced apoptosis of INS-1 β-cells. Biochem J. 438(1), 177-189 (2011).
Cas No. | 6063-36-1 | SDF | |
别名 | Cer(d18:0/24:0) | ||
化学名 | N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)heptadecyl]-tetracosanamide | ||
Canonical SMILES | OC[C@H](NC(CCCCCCCCCCCCCCCCCCCCCCC)=O)[C@@H](CCCCCCCCCCCCCCC)O | ||
分子式 | C42H85NO3 | 分子量 | 652.1 |
溶解度 | DMF: 0.15 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.5335 mL | 7.6675 mL | 15.3351 mL |
5 mM | 0.3067 mL | 1.5335 mL | 3.067 mL |
10 mM | 0.1534 mL | 0.7668 mL | 1.5335 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。